nach oben

Erschienen in:

29.10.2018 | Preclinical study

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

verfasst von: Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T. Opferman, Michael H. Cardone, Dirk Jäger, Klaus Podar

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC). Mcl-1 inhibitors, such as the BH3-mimetic EU-5346, therefore represent an exciting new class of targeting agents and are a current focus of widespread cancer-drug development efforts.

Methods

ONCOMINE analysis was utilized to compare expression profiles of Bcl-2 family members across all major BC subgroups. Potential toxicities of EU-5346 were evaluated using iPS-generated cardiomyocytes, blood cells and astrocytes. The anti-BC cell activity of EU-5346-based therapies was evaluated using [³H]-thymidine uptake and spheroid-forming assays as well as immunoblotting and the Chou-Talalay method. Protein level-based activity of EU-5346, the specific anti-Bcl-2 inhibitor ABT-199 and the specific anti-Bcl-x_L inhibitor WEHI-539 was verified in Mcl-1^Δ/null versus Mcl-1^wt/wt MEFs.

Results

We previously demonstrated significant anti-tumor activity of EU-5346 in all BC subtypes. Our present results go further and suggest that EU-5346 may induce limited adverse events such as cardiotoxicity, hematotoxicity, and neurotoxicity, frequently observed with other BH3 mimetics. As demonstrated by our mathematical scoring model, the prediction of EU-5643-induced IC₅₀ not only relies on the protein level of Mcl-1 but also on Bak, Bim, and Noxa. Synergistic anti-BC activity of low-dose EU-5346 with the BH3 mimetics ABT-199 or WEHI-539 was observed only in those BC cells expressing Bcl-2 or Bcl-x_L, respectively. Similarly, when combined with tamoxifen or trastuzumab, low-dose EU-5346 induced significant anti-BC activity in hormone receptor positive or Her2-positive BC cells, respectively. Finally, EU-5346 in combination with paclitaxel induced synergistic anti-BC activity in both paclitaxel-sensitive and paclitaxel-resistant TNBC cells.

Conclusion

These data strongly support the further clinical development of EU-5346 to improve BC patient survival.

Nur mit Berechtigung zugänglich

Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412 CrossRef

Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337. https://doi.org/10.1038/sj.onc.1210220 CrossRefPubMedPubMedCentral

Vogler M, Dinsdale D, Dyer MJS, Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360–367. https://doi.org/10.1038/cdd.2008.137 CrossRefPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

Montero J, Letai A (2018) Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Diff 25:56–64. https://doi.org/10.1038/cdd.2017.183 CrossRef

Thomas LW, Lam C, Edwards SW (2010) Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981–2989. https://doi.org/10.1016/j.febslet.2010.05.061 CrossRefPubMed

Germain M, Duronio V (2007) The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function. J Biol Chem 282:32233–32242. https://doi.org/10.1074/jbc.M706408200 CrossRefPubMed

Yang T, Kozopas KM, Craig RW (1995) The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 128:1173–1184CrossRefPubMed

Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619CrossRefPubMed

10.

Del Gaizo Moore V, Letai A (2013) BH3 profiling–measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332:202–205. https://doi.org/10.1016/j.canlet.2011.12.021 CrossRefPubMed

11.

Oda E, Ohki R, Murasawa H et al (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053–1058CrossRefPubMed

12.

Wei G, Margolin AA, Haery L et al (2012) Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21:547–562. https://doi.org/10.1016/j.ccr.2012.02.028 CrossRefPubMedPubMedCentral

13.

Beroukhim R, Mermel CH, Porter D et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905. https://doi.org/10.1038/nature08822 CrossRefPubMedPubMedCentral

14.

Leverson JD, Phillips DC, Mitten MJ et al (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7:279ra40. https://doi.org/10.1126/scitranslmed.aaa4642 CrossRefPubMed

15.

Leverson JD, Zhang H, Chen J et al (2015) Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 6:e1590. https://doi.org/10.1038/cddis.2014.561 CrossRefPubMedPubMedCentral

16.

Abulwerdi F, Liao C, Liu M et al (2014) A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 13:565–575. https://doi.org/10.1158/1535-7163.MCT-12-0767 CrossRefPubMed

17.

Kotschy A, Szlavik Z, Murray J et al (2016) The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538:477–482. https://doi.org/10.1038/nature19830 CrossRefPubMed

18.

Belmar J, Fesik SW (2015) Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther 145:76–84. https://doi.org/10.1016/j.pharmthera.2014.08.003 CrossRefPubMed

19.

Nguyen M, Marcellus RC, Roulston A et al (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104:19512–19517. https://doi.org/10.1073/pnas.0709443104 CrossRefPubMed

20.

Richard DJ, Lena R, Bannister T et al (2013) Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem 21:6642–6649. https://doi.org/10.1016/j.bmc.2013.08.017 CrossRefPubMed

21.

Bashari MH, Fan F, Vallet S et al (2016) Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res 18:26. https://doi.org/10.1186/s13058-016-0686-4 CrossRefPubMedPubMedCentral

22.

Ding Q, He X, Hsu J-M et al (2007) Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27:4006–4017. https://doi.org/10.1128/MCB.00620-06 CrossRefPubMed

23.

Campbell KJ, Dhayade S, Ferrari N et al (2018) MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis 9:19. https://doi.org/10.1038/s41419-017-0035-2 CrossRefPubMedPubMedCentral

24.

Williams MM, Lee L, Hicks DJ et al (2017) Key survival factor, Mcl-1, correlates with sensitivity to combined Bcl-2/Bcl-xL blockade. Mol Cancer Res 15:259–268. https://doi.org/10.1158/1541-7786.MCR-16-0280-T CrossRefPubMed

25.

Merino D, Whittle JR, Vaillant F et al (2017) Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med 9:eaam7049. https://doi.org/10.1126/scitranslmed.aam7049 CrossRefPubMed

26.

Wertz IE, Kusam S, Lam C et al (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471:110–114. https://doi.org/10.1038/nature09779 CrossRefPubMed

27.

Placzek WJ, Wei J, Kitada S et al (2010) A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 1:e40. https://doi.org/10.1038/cddis.2010.18 CrossRefPubMedPubMedCentral

28.

Booy EP, Henson ES, Gibson SB (2011) Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 30:2367–2378. https://doi.org/10.1038/onc.2010.616 CrossRefPubMedPubMedCentral

29.

van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389–399. https://doi.org/10.1016/j.ccr.2006.08.027 CrossRefPubMedPubMedCentral

30.

Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681. https://doi.org/10.1038/nature03579 CrossRefPubMed

31.

Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421–3428. https://doi.org/10.1158/0008-5472.CAN-07-5836 CrossRefPubMed

32.

Opferman JT, Letai A, Beard C et al (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426:671–676CrossRefPubMed

33.

Podar K, Gouill SL, Zhang J et al (2008) A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 27:721–731CrossRefPubMed

34.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166–180CrossRefPubMedPubMedCentral

35.

Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. https://doi.org/10.1016/j.cell.2007.11.019 CrossRefPubMed

36.

Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309–324. https://doi.org/10.1038/nprot.2008.226 CrossRefPubMed

37.

Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947 CrossRefPubMed

38.

Bannister T, Koenig M, He Y, Mishra J, Spicer T, Minond D, Saldanha A, Mercer BA, Cameron M, Lena R, Carlson N, Richard D, Cardone MHP (2013) ML311: A Small Molecule that Potently and Selectively Disrupts the Protein-Protein Interaction of Mcl-1 and Bim: A Probe for Studying Lymphoid Tumo… In: Probe Reports from NIH Mol. Libr. Progr. [Internet]. Bethesda Natl. Cent. Biotechnol. Inf. http://www.ncbi.nlm.nih.gov/pubmed/23762927. Accessed 8 Jun 2015

39.

Wang X, Bathina M, Lynch J et al (2013) Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 27:1351–1364. https://doi.org/10.1101/gad.215855.113 CrossRefPubMedPubMedCentral

40.

Nikhil K, Shah K (2017) The Cdk5-Mcl-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer’s disease. J Cell Sci 130:3023–3039. https://doi.org/10.1242/jcs.205666 CrossRefPubMedPubMedCentral

41.

Perciavalle RM, Stewart DP, Koss B et al (2012) Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 14:575–583. https://doi.org/10.1038/ncb2488 CrossRefPubMedPubMedCentral

42.

Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW (2015) Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Diff 22:2098–2106. https://doi.org/10.1038/cdd.2015.73 CrossRef

43.

Zhang Z, Liu Y, Song T et al (2013) An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. Br J Cancer 108:1870–1878. https://doi.org/10.1038/bjc.2013.152 CrossRefPubMedPubMedCentral

44.

Deng J, Carlson N, Takeyama K et al (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12:171–185. https://doi.org/10.1016/j.ccr.2007.07.001 CrossRefPubMed

45.

Wei S-H, Dong K, Lin F et al (2008) Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol 62:1055–1064. https://doi.org/10.1007/s00280-008-0697-7 CrossRefPubMed

46.

Konopleva M, Contractor R, Tsao T et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375–388. https://doi.org/10.1016/j.ccr.2006.10.006 CrossRefPubMed

47.

Goldsmith KC, Lestini BJ, Gross M et al (2010) BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ 17:872–882. https://doi.org/10.1038/cdd.2009.171 CrossRefPubMed

48.

Morales AA, Kurtoglu M, Matulis SM et al (2011) Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 118:1329–1339. https://doi.org/10.1182/blood-2011-01-327197 CrossRefPubMedPubMedCentral

49.

Al-Harbi S, Hill BT, Mazumder S et al (2011) An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 118:3579–3590. https://doi.org/10.1182/blood-2011-03-340364 CrossRefPubMedPubMedCentral

50.

Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW (2015) Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. https://doi.org/10.1038/cdd.2015.73 PubMedPubMedCentralCrossRef

51.

Balko JM, Giltnane JM, Wang K et al (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4:232–245. https://doi.org/10.1158/2159-8290.CD-13-0286 CrossRefPubMed

Titel: Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
verfasst von: Sonia Vallet
Fengjuan Fan
Stefano Malvestiti
Martin Pecherstorfer
Martin Sattler
Andreas Schneeweiss
Henning Schulze-Bergkamen
Joseph T. Opferman
Michael H. Cardone
Dirk Jäger
Klaus Podar
Publikationsdatum: 29.10.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5022-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Survivorship care visits in a high-risk population of breast cancer survivors

Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis

Trends in stage at diagnosis for young breast cancer patients in the United States

Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines

Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie